Business Context and Reporting Period
Company: OKYO Pharma Ltd
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: July 22, 2026
Context: The filing announces an insider transaction involving the purchase of company shares by an executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific equity transaction.
Material Changes
Insider Transaction: Gary S. Jacob, PhD, Chief Development Officer and Director, purchased 3,500 ordinary shares of the Company on NASDAQ.
Transaction Price: $1.40 per share.
Post-Transaction Holdings: 112,420 ordinary shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the disclosure of the share purchase.
Investor Verification Checklist
- Verify the total number of outstanding shares to assess the percentage ownership increase for Gary S. Jacob.
- Confirm the current market price of OKYO Pharma shares relative to the $1.40 purchase price.
- Review the attached Exhibit 99.1 for any additional context regarding the motivation for the purchase.
- Check subsequent filings for any changes in the Company's capitalization table.